Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer

1 Apr 2012

Abstract excerpt

BACKGROUND: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. However, no standardized method exists for assessing the EGFR mutation status...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22514499
DOI: 10.3747/co.19.862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung CancerPMID 22514499Read ↗

A Comparison of Methods for EGFR Mutation Testing in Non–Small Cell Lung CancerSemantic proximity Read ↗

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.Semantic proximity Read ↗

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Semantic proximity Read ↗

EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.Semantic proximity Read ↗

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.Semantic proximity Read ↗

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancerSemantic proximity Read ↗

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.Semantic proximity Read ↗

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.Semantic proximity Read ↗

Detection of common and less frequent EGFR mutations in cytological samples of lung cancer.Semantic proximity Read ↗

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).Semantic proximity Read ↗

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.Semantic proximity Read ↗

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.